Annual EBITDA
-$11.46 M
+$8.01 M+41.15%
December 31, 2023
Summary
- As of February 7, 2025, PCSA annual EBITDA is -$11.46 million, with the most recent change of +$8.01 million (+41.15%) on December 31, 2023.
- During the last 3 years, PCSA annual EBITDA has risen by +$2.87 million (+20.05%).
- PCSA annual EBITDA is now -12407.42% below its all-time high of -$91.60 thousand, reached on December 31, 2016.
Performance
PCSA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$3.42 M
-$342.80 K-11.12%
September 30, 2024
Summary
- As of February 7, 2025, PCSA quarterly EBITDA is -$3.42 million, with the most recent change of -$342.80 thousand (-11.12%) on September 30, 2024.
- Over the past year, PCSA quarterly EBITDA has dropped by -$615.20 thousand (-21.90%).
- PCSA quarterly EBITDA is now -16724.76% below its all-time high of $20.60 thousand, reached on June 30, 2017.
Performance
PCSA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$11.79 M
-$1.26 M-11.94%
September 30, 2024
Summary
- As of February 7, 2025, PCSA TTM EBITDA is -$11.79 million, with the most recent change of -$1.26 million (-11.94%) on September 30, 2024.
- Over the past year, PCSA TTM EBITDA has dropped by -$1.62 million (-15.99%).
- PCSA TTM EBITDA is now -45936.72% below its all-time high of -$25.60 thousand, reached on June 30, 2017.
Performance
PCSA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PCSA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +41.1% | -21.9% | -16.0% |
| 3 y3 years | +20.1% | +38.9% | +39.5% |
| 5 y5 years | -195.5% | +38.9% | +39.5% |
PCSA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -6.3% | +41.1% | -58.0% | +41.6% | -16.0% | +42.6% |
| 5 y | 5-year | -267.2% | +41.1% | -469.8% | +66.4% | -306.6% | +42.6% |
| alltime | all time | <-9999.0% | +41.1% | <-9999.0% | +66.4% | <-9999.0% | +42.6% |
Processa Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3.42 M(+11.1%) | -$11.79 M(+11.9%) |
| Jun 2024 | - | -$3.08 M(+9.7%) | -$10.53 M(+3.6%) |
| Mar 2024 | - | -$2.81 M(+13.8%) | -$10.16 M(-11.3%) |
| Dec 2023 | -$11.46 M(-41.2%) | -$2.47 M(+13.9%) | -$11.46 M(-21.5%) |
| Sep 2023 | - | -$2.17 M(-20.2%) | -$14.59 M(-20.2%) |
| Jun 2023 | - | -$2.71 M(-33.9%) | -$18.28 M(-11.0%) |
| Mar 2023 | - | -$4.11 M(-26.7%) | -$20.54 M(+5.5%) |
| Dec 2022 | -$19.47 M(+80.7%) | -$5.60 M(-4.4%) | -$19.47 M(+14.3%) |
| Sep 2022 | - | -$5.86 M(+17.8%) | -$17.04 M(+21.3%) |
| Jun 2022 | - | -$4.97 M(+64.1%) | -$14.04 M(+15.4%) |
| Mar 2022 | - | -$3.03 M(-4.4%) | -$12.16 M(+9.4%) |
| Dec 2021 | -$10.78 M(-24.8%) | -$3.17 M(+10.7%) | -$11.12 M(-38.7%) |
| Sep 2021 | - | -$2.86 M(-7.4%) | -$18.14 M(+0.6%) |
| Jun 2021 | - | -$3.10 M(+55.6%) | -$18.03 M(+16.1%) |
| Mar 2021 | - | -$1.99 M(-80.5%) | -$15.53 M(+8.4%) |
| Dec 2020 | -$14.33 M(+359.3%) | -$10.19 M(+269.9%) | -$14.33 M(+195.4%) |
| Sep 2020 | - | -$2.75 M(+358.3%) | -$4.85 M(+67.4%) |
| Jun 2020 | - | -$601.00 K(-23.5%) | -$2.90 M(-10.3%) |
| Mar 2020 | - | -$785.40 K(+10.6%) | -$3.23 M(+3.5%) |
| Dec 2019 | -$3.12 M(-19.5%) | -$710.40 K(-11.4%) | -$3.12 M(+6.0%) |
| Sep 2019 | - | -$801.60 K(-14.0%) | -$2.94 M(-1.8%) |
| Jun 2019 | - | -$932.60 K(+38.0%) | -$3.00 M(-8.9%) |
| Mar 2019 | - | -$675.60 K(+26.8%) | -$3.29 M(-15.2%) |
| Dec 2018 | -$3.88 M | -$532.90 K(-37.6%) | -$3.88 M(-22.3%) |
| Sep 2018 | - | -$854.10 K(-30.4%) | -$4.99 M(+16.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | -$1.23 M(-2.9%) | -$4.29 M(+41.0%) |
| Mar 2018 | - | -$1.26 M(-23.2%) | -$3.04 M(+69.6%) |
| Dec 2017 | -$1.80 M(+1860.0%) | -$1.64 M(+938.5%) | -$1.80 M(+903.5%) |
| Sep 2017 | - | -$158.30 K(-868.4%) | -$178.90 K(+598.8%) |
| Jun 2017 | - | $20.60 K(-250.4%) | -$25.60 K(-14.7%) |
| Mar 2017 | - | -$13.70 K(-50.2%) | -$30.00 K(-67.3%) |
| Dec 2016 | -$91.60 K(-96.3%) | -$27.50 K(+450.0%) | -$91.70 K(-68.4%) |
| Sep 2016 | - | -$5000.00(-130.9%) | -$290.00 K(-33.3%) |
| Jun 2016 | - | $16.20 K(-121.5%) | -$434.90 K(-80.5%) |
| Mar 2016 | - | -$75.40 K(-66.6%) | -$2.24 M(-10.9%) |
| Dec 2015 | -$2.51 M(-14.7%) | -$225.80 K(+50.6%) | -$2.51 M(-12.8%) |
| Sep 2015 | - | -$149.90 K(-91.6%) | -$2.88 M(-12.2%) |
| Jun 2015 | - | -$1.78 M(+411.6%) | -$3.28 M(+54.7%) |
| Mar 2015 | - | -$348.70 K(-41.2%) | -$2.12 M(-28.0%) |
| Dec 2014 | -$2.94 M(+15.6%) | -$593.20 K(+7.8%) | -$2.94 M(-3.1%) |
| Sep 2014 | - | -$550.10 K(-12.1%) | -$3.03 M(-0.6%) |
| Jun 2014 | - | -$625.60 K(-46.7%) | -$3.05 M(+1.2%) |
| Mar 2014 | - | -$1.17 M(+71.0%) | -$3.02 M(+18.7%) |
| Dec 2013 | -$2.54 M(+17.7%) | -$685.90 K(+20.4%) | -$2.54 M(+0.9%) |
| Sep 2013 | - | -$569.60 K(-3.5%) | -$2.52 M(+0.3%) |
| Jun 2013 | - | -$590.30 K(-15.5%) | -$2.51 M(+8.0%) |
| Mar 2013 | - | -$698.20 K(+5.3%) | -$2.33 M(+7.7%) |
| Dec 2012 | -$2.16 M | -$663.20 K(+17.9%) | -$2.16 M(+44.3%) |
| Sep 2012 | - | -$562.40 K(+39.0%) | -$1.50 M(+60.1%) |
| Jun 2012 | - | -$404.50 K(-23.8%) | -$935.60 K(+76.2%) |
| Mar 2012 | - | -$531.10 K | -$531.10 K |
FAQ
- What is Processa Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Processa Pharmaceuticals?
- What is Processa Pharmaceuticals annual EBITDA year-on-year change?
- What is Processa Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Processa Pharmaceuticals?
- What is Processa Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Processa Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Processa Pharmaceuticals?
- What is Processa Pharmaceuticals TTM EBITDA year-on-year change?
What is Processa Pharmaceuticals annual EBITDA?
The current annual EBITDA of PCSA is -$11.46 M
What is the all time high annual EBITDA for Processa Pharmaceuticals?
Processa Pharmaceuticals all-time high annual EBITDA is -$91.60 K
What is Processa Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, PCSA annual EBITDA has changed by +$8.01 M (+41.15%)
What is Processa Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of PCSA is -$3.42 M
What is the all time high quarterly EBITDA for Processa Pharmaceuticals?
Processa Pharmaceuticals all-time high quarterly EBITDA is $20.60 K
What is Processa Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, PCSA quarterly EBITDA has changed by -$615.20 K (-21.90%)
What is Processa Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of PCSA is -$11.79 M
What is the all time high TTM EBITDA for Processa Pharmaceuticals?
Processa Pharmaceuticals all-time high TTM EBITDA is -$25.60 K
What is Processa Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, PCSA TTM EBITDA has changed by -$1.62 M (-15.99%)